Eyenuk Inc., a Woodland Hills company that uses artificial technology to screen for diabetic complications in the eyes, will expand its service to a diabetes treatment center in Germany.
The company’s EyeArt technology will be available at the Diabetes Center Megentheim in Bad Mergentheim, Germany. The system uses artificial intelligence to read retinal images and screen for diabetic retinopathy, the leading cause of vision loss among adults, according to a study by the Institute for Ophthalmic Research in Tübingen, Germany.
Eyenuk announced the expansion Oct. 2.
“We are gratified to see the global adoption for the EyeArt system and the opportunity that the technology offers to primary care and diabetes clinics,” Kaushal Solanki, Eyenuk chief executive, said in statement. “The EyeArt system will enable millions of patients to be screened in real time for early disease detection.”
Eyenuk is using its retinal analysis technology to identify and track the progression of diseases including glaucoma, age-related macular degeneration, risk of stroke, cardiovascular risk and Alzheimer’s disease.